From: Neratinib for HER2-positive breast cancer with an overlooked option
Endpoint (NALA trial) | Neratinib + capecitabine (N + C) | Lapatinib + capecitabine (L + C) | P |
Mean PFS | 8.8 months | 6.6 months | 0.0059 |
Median PFS | 5.6 months | 5.5 months | Â |
6-month PFS rate | 47.2% | 37.8% | Â |
12-month PFS rate | 28.8% | 14.8% | Â |
18-month PFS rate | 16.3% | 7.4% | Â |
Mean OS | 24.0 months | 22.2 months | 0.2086 |
Median OS | 21.0 months | 18.7 months | Â |
Cumulative incidence of intervention for CNS disease | 22.8% | 29.2% | 0.0430 |
ORR | 32.8% | 26.7% | 0.1201 |
DOR | 8.5 months | 5.6 months | 0.0004 |
Endpoint (HER2CLIMB trial) | Tucatinib combination | Placebo combination | P |
Median PFS | 7.6 months | 4.9 months | < 0.00001 |
1-year PFS rate | 29% | 14% | Â |
Median OS | 24.7 months | 19.2 months | 0.004 |
2-year OS rate | 51% | 40% | Â |
Median CNS-PFS | 9.9 months | 4.6 months | Â |
Median CNS-OS | 21.6 months | 12.5 months | Â |
Confirmed ORR-IC | 47.3% | 20.0% | Â |
median DOR-IC | 8.6% | 3.0% | Â |
Endpoint (PHENIX trial) | Pyrotinib + capecitabine | Placebo + capecitabine | P |
Median PFS | 11.1 months | 4.1 months | < 0.001 |
Median CNS-PFS | 6.9 months | 4.2 months | 0.011 |
ORR | 68.6% | 16.0% | < 0.001 |
DOR | 12.2 months | 4.2 months | < 0.001 |
DCR | 91.9% | 64.9% | < 0.001 |
CBR | 76.8% | 22.3% | < 0.001 |